Skip to content

CyberKnife Based Hypofractionated Radiotherapy for Vertebral Hemangiomas

CyberKnife Based Hypofractionated Radiotherapy Versus Conventional Linac Based Radiotherapy for Painful Vertebral Hemangiomas - Controlled Randomized Clinical Trial.

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02332408
Acronym
CKHRTVH
Enrollment
80
Registered
2015-01-06
Start date
2014-09-30
Completion date
2021-09-30
Last updated
2015-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemangioma of Vertebral Column

Keywords

vertebral hemangioma, conventional radiotherapy, Cyber Knife radiotherapy, randomized trial, radioablation

Brief summary

Clinical objective of the study is to compare the analgesic effect, toxicity and pathologic effect in the tumors of two radiotherapy schedules used for patients suffering from painful vertebral haemangiomas

Detailed description

Hemangiomas are frequent vertebral lesions (12% of the whole human population) but only 1% displays any clinical symptoms . The most common symptom is local pain, usually non responding for non-steroid anti-inflammatory drugs. Radiation therapy usually does not result calcification or the tumor regression, but significantly reduces the pain intensity or eliminates it. Currently, the most common RT schedule is conventional radiotherapy using fraction dose (fd) of 2 Gy delivered to the total dose (TD) varying from36 Gy to 40 Gy. The results in pain reduction achieved after larger total doses are better that led us to use radioablative techniques. This procedure is associated with a probability of better analgesic effect and the good local effect (calcification and / or regression of laesion) with high safety of radiation delivery using tracking based cybernetic microradiosurgery (CyberKnife). The comparison of two modalities of radiation therapy (conventional \[fd 2 Gy, TD 36 Gy\] and hypofractionated \[fd 5 Gy, TD 25 Gy\]) used for treatment of painful vertebral hemangioma patients will be performed in the phase III randomized study. 80 patients will be enrolled in this study. All patients will be planned (RT) on the base of CT/MRI fusion. Patients will be controlled 1, 3, 6, 9, 12 months after treatment completion and, next every each 6 months. Pain relief, analgesics uptake, local effect (MRI and Technetium - 99m-labelled RBC(red blood cell) scintigraphy) and eventual toxicity will be checked during follow-up (FU).

Interventions

RADIATIONCybernetic microradiosurgery

Cybernetic microradiosurgery (6MV) using tracking to TD 25Gy given in five fraction (5Gy p fr) two or three days a week, during 2 weeks

RADIATIONConventional radiotherapy

Conventionally fractionated linac based external beam radiation therapy - EBRT, (conformal or dynamic) to the TD of 36 Gy, in 2.0 Gy per fraction 5 days a week over the period of 3.5 weeks)

Sponsors

Maria Sklodowska-Curie National Research Institute of Oncology
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
25 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

1. Confirmed vertebral hemangioma , 2. Lesion visible in CT and MR 3. Pain located in area of the lesion 4. Informed consent for participation in the study and for radiotherapy in interested area

Exclusion criteria

1. Any previous radiotherapy in region of treated hemangioma 2. Spinal damage or disease that may be associated with an increased radiosensitivity 3. The coexistence of the vertebral morphological changes at the level of hemangioma causing pressure on the nerve roots and / or spinal cord causing pain located in that area 4. Neurological deficits caused by the presence of hemangioma (patients should be considered for surgery) 5. Contradictions for MRI 6. Lack of informed consent.

Design outcomes

Primary

MeasureTime frameDescription
Analgetic effect2 yearsrate of pain relief

Secondary

MeasureTime frame
Identification of radiologic prognostic and predictal factors of response to external beam radiotherapy (radiosurgery compared to conventional)2 years
Identification of biochemical and physical prognostic factors of response to external beam radiotherapy (radiosurgery compared to conventional)2 years

Countries

Poland

Contacts

Primary ContactLeszek Miszczyk, MD, PhD
leszek@io.gliwice.pl0048322788001

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 13, 2026